Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 17, 15, 15, 26, 43.
All papers from the last 12 months
501 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individualsHum Vaccin Immunother2026 Dec 31PMID 42118165
- Generative AI-enabled neoantigen vaccine engineering: From tumor antigen discovery to personalized construct design and translational validationBiotechnol Adv2026 DecPMID 42679971Review
- Delivering the blueprint: Advances and challenges in mRNA therapeutics for the respiratory systemInt J Pharm X2026 DecPMID 42662466Review
- A Self-assembly Carrier-Free Nanovaccine based on Fluorinated CpG and Neoantigen Peptides for Hepatocellular Carcinoma ImmunotherapyInt J Pharm X2026 DecPMID 42491306
- Immunotherapy in pediatric bone sarcomas: Current progress and future directionsHum Vaccin Immunother2026 DecPMID 42366590Review
- Preventive and therapeutic efficacy of mRNA/LNP vaccines encoding HPV16 E6 and E7 in an early-intervention HPV tumor mouse modelsHum Vaccin Immunother2026 DecPMID 42301768
- mRNA vaccines and therapeutics beyond COVID-19: A review of the global clinical development landscape, low- and middle-income countries involvement and relevance to their contextsHum Vaccin Immunother2026 DecPMID 41781347Review
- Current landscape of clinical trials for mRNA-based therapeuticsHum Vaccin Immunother2026 DecPMID 41729563Review
- Light on dark matter: Epigenetic drugs as a tool to reveal the hidden antigen repertoireBiochem Biophys Res Commun2026 Nov 5PMID 42822054Review
- Dendritic cell‑based vaccines for colorectal cancer: Mechanisms, clinical progress and future directions (Review)Int J Oncol2026 NovPMID 42695424Review
More oncology trends
All specialties →Antibody-drug conjugates
Antibodies linked to chemotherapy, such as trastuzumab deruxtecan.
Key point: Recent positive phase III trial data have further incorporated ADCs into standard of care in several solid tumours, while predictive biomarker development remains essential.
Perioperative immunotherapy
Immune checkpoint inhibitors given before and after cancer surgery.
Bispecific antibodies in solid tumours
Bispecific antibodies such as tarlatamab, amivantamab and ivonescimab.
AI in cancer pathology
Deep learning on digital pathology slides.
Cell therapy in solid tumours
CAR-T, TIL and TCR-T therapies for solid tumours.
CDK4/6 inhibitors in breast cancer
Palbociclib, ribociclib and abemaciclib in hormone receptor-positive breast cancer.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("mRNA vaccine*"[tiab] OR "personalized cancer vaccine*"[tiab] OR "neoantigen vaccine*"[tiab] OR "individualized neoantigen"[tiab]) AND (cancer[tiab] OR melanoma[tiab] OR tumor*[tiab] OR tumour*[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.